The safety of incretin based drugs

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Montori, Victor M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST;

DRUG COST; DRUG SAFETY; EDITORIAL; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; RISK FACTOR; SOCIAL STATUS; SYSTEMATIC REVIEW;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; PANCREATITIS;

EID: 84899557424     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g2779     Document Type: Editorial

References (6)

1. Li L, Shen J, Bala MB, Busse JW, Ebrahim S, Vandvik PO, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014:348:g2366.
2. Faillie J-L, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretins and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ 2014:348:g2780.
3. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014;37(suppl 1):s14-80.
4. Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-25.
5. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014;370:794-7.
6. Mullan RJ, Montori VM, Shah ND, Christianson TJ, Bryant SC, Guyatt GH, et al. The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med 2009;28;169:1560-8.